Sodium–glucose cotransporter 2 (SGLT2) inhibitors are underutilized in people with type 2 diabetes after coronary artery bypass grafting (CABG). This study investigated the association of the presence of an endocrinologist on treatment teams with SGLT2 inhibitor prescription in patients with type 2 diabetes after CABG. The presence of an endocrinologist was associated with a more than twofold increase in the odds of obtaining an SGLT2 inhibitor prescription. This finding suggests that involving endocrinologists in these patients’ postoperative care may improve prescription and use of SGLT2 inhibitors after CABG.
This content is only available via PDF.
©2025 by the American Diabetes Association
2025
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at https://www.diabetesjournals.org/journals/pages/license.
You do not currently have access to this content.
